Multiple sclerosis (MS) is a chronic progressive potentially disabling disorder with considerable social impact and economic consequences despite its relatively limited prevalence. It is the major cause of non‐traumatic disability in young adults [1]. There are now 2.8 million people worldwide who have multiple sclerosis (MS), according to the most extensive global study to date. That means every 5 minutes, someone, somewhere in the world is diagnosed with MS. Most people with MS are diagnosed between the ages of 20 and 50, and it affects women three times more than men [2]. Pathologically, MS is characterized by numerous, discrete lesions (called plaques) scattered throughout the CNS white matter. The essential feature of these lesions is loss of the myelin sheath with preservation of the axon. The presence of these lesions causes multiple, varied symptoms and signs of neurological dysfunction. One common initial symptom is optic neuritis (ON). Other sensory symptoms may include numbness, tingling in the hands or feet, cold or burning pain, and dizziness. Motor symptoms may include impaired coordination, imbalance, weakness, intention tremor, and spastic tone [3].

Suez Canal University, Hospital